Home > Search Results: Gökbuget, Nicola
  Search Tips
Simple Search
Search collections:
Sort by: Display results: Output format:
UAB Digital Repository of Documents 3 records found  Search took 0.00 seconds. 
1.
18 p, 2.5 MB The EHA Research Roadmap : Malignant Lymphoid Diseases / Dreyling, Martin (LMU Hospital (Alemanya)) ; André, Marc (Université Catholique de Louvain (bèlgica)) ; Gökbuget, Nicola (Goethe University (Alemanya)) ; Tilly, Hervé (Centre Henri Becquerel and Université de Rouen (França)) ; Jerkeman, Mats (Skåne University and Lund University (Suècia)) ; Gribben, John (Queen Mary University of London (Regne Unit)) ; Ferreri, Andrés (IRCCS San Raffaele Scientific Institute (Itàlia)) ; Morel, Pierre (CHU Amiens Picardie (França)) ; Stilgenbauer, Stephan (Universität Ulm (Alemanya)) ; Fox, Christopher (University of Nottingham (Regne Unit)) ; Maria Ribera, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zweegman, Sonja (Amsterdam UMC (Països Baixos)) ; Aurer, Igor (University of Zagreb (Zagreb)) ; Bödör, Csaba (Semmelweis University (Hongria)) ; Burkhardt, Birgit (Pädiatrische Hämatologie und Onkologie (Alemanya)) ; Buske, Christian (University Hospital of Ulm (Alemanya)) ; Dollores Caballero, Maria (El Instituto de Investigación Biomédica de Salamanca (Salamanca, Espanya)) ; Campo, Elias (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Chapuy, Bjoern (Berlin Institute of Health (Alemanya)) ; Davies, Andrew (University of Southampton (Regne Unit)) ; de Leval, Laurence (Lausanne University Switzerland (Suïssa)) ; Doorduijn, Jeanette (University Medical Center Rotterdam the Netherlands (Països Baixos)) ; Federico, Massimo (GVM Care & Research (Itàlia)) ; Gaulard, Philippe (Hôpital Henri Mondor (França)) ; Gay, Francesca (AOU Città Della Salute e Della Scienza (Itàlia)) ; Ghia, Paolo (IRCCS Ospedale San Raffaele (Itàlia)) ; Grønbæk, Kirsten (University of Copenhagen (Dinamarca)) ; Goldschmidt, Hartmut (University Hospital Heidelberg (Alemanya)) ; Kersten, Marie-Jose (Cancer Center Amsterdam and LYMMCARE the Netherlands (Països Baixos)) ; Kiesewetter, Barbara (Medical University of Vienna (Àustria)) ; Landman-Parker, Judith (Sorbonne Université APHP/hôpital A Trousseau (França)) ; Le Gouill, Steven (Clinique du Centre Hospitalier Universitaire (CHU) de Nantes (França)) ; Lenz, Georg (Medical University Hospital Münster (Alemanya)) ; Leppä, Sirpa (Helsinki University Hospital Comprehensive Cancer Centre Finland (Finlandia)) ; López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ; Macintyre, Elizabeth (Assistance Publique-Hôpitaux de Paris (França)) ; Mantega, Maria Victoria Mateos (Universidad de Salamanca (Salamanca, Espanya)) ; Moreau, Philippe (University Hospital Hotel-Dieu (França)) ; Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Nadel, Bertrand (Aix Marseille Univ (França)) ; Okosun, Jessica (Queen Mary University of London (Regne Unit)) ; Owen, Roger (St James's Institute of Oncology (Regne Unit)) ; Pospisilova, Sarka (University Hospital Brno (Txèquia)) ; Pott, Christiane (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Robak, Tadeusz (Medical University of Lodz (Polònia)) ; Spina, Michelle (National Cancer Institute (Itàlia)) ; Stamatopoulos, Kostas (Centre for Research and Technology Hellas Greece (Grècia)) ; Stary, Jan (Charles University Prague University Hospital Czech Republic (Txèquia)) ; Tarte, Karin (Immunology and Cell Therapy Lab at Rennes University Hospital (França)) ; Tedeschi, Allessandra (Niguarda Hospital Milano (Itàlia)) ; Thieblemont, Catherine (Assistance Publique-Hôpitaux de Paris (França)) ; Trappe, Ralf Ulrich (DIAKO Hospital Bremen (Alemanya)) ; Trümper, Lorenz H. (University Medicine Goettingen (Alemanya)) ; Salles, Gilles (Weill Cornell Medicine (Estats Units)) ; Universitat Autònoma de Barcelona
2022 - 10.1097/HS9.0000000000000726
HemaSphere, Vol. 6 (may 2022)  
Detailed record - Creative Commons
2.
6 p, 186.9 KB Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab / Topp, Max S. (Universitätsklinikum Würzburg) ; Gökbuget, Nicola (Goethe University) ; Zugmaier, Gerhard (Amgen GmbH) ; Stein, Anthony S. (Gehr Family Center for Leukemia Research. City of Hope) ; Dombret, Hervé (Saint Louis Hospital. University of Paris) ; Chen, Yuqi (Amgen. Inc) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bargou, Ralf C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ; Horst, Heinz-August (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Kantarjian, H. M. (The University of Texas MD Anderson Cancer Center) ; Universitat Autònoma de Barcelona
Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells expressing CD19. Methods: A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was conducted. [...]
2021 - 10.1002/cncr.33298
Cancer, Vol. 127 Núm. 4 (15 2021) , p. 554-559  
Detailed record - Creative Commons
3.
13 p, 2.7 MB Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia / Gökbuget, Nicola (University Hospital of Frankfurt (Alemanya)) ; Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ; Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ; Bruggemann, Monika (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Doubek, Michael (University Hospital Brno (República Txeca)) ; Foà, Robin (Sapienza University of Rome) ; Hoelzer, Dieter (University Hospital of Frankfurt (Alemanya)) ; Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ; Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ; Parovichnikova, Elena (National Research Center for Hematology, Moscow) ; Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Schoonen, Marieke (Amgen Ltd, London) ; Stieglmaier, Julia M. (Amgen GmBH, Munich) ; Zugmaier, Gerhard (Amgen GmBH, Munich) ; Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ; Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with